JPH09227404A - 不妊症を治療するための製薬学的製剤 - Google Patents
不妊症を治療するための製薬学的製剤Info
- Publication number
- JPH09227404A JPH09227404A JP9022359A JP2235997A JPH09227404A JP H09227404 A JPH09227404 A JP H09227404A JP 9022359 A JP9022359 A JP 9022359A JP 2235997 A JP2235997 A JP 2235997A JP H09227404 A JPH09227404 A JP H09227404A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- antagonist
- ovulation
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 20
- 208000000509 infertility Diseases 0.000 title claims abstract description 9
- 230000036512 infertility Effects 0.000 title claims abstract description 9
- 231100000535 infertility Toxicity 0.000 title claims abstract description 9
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims abstract description 20
- 102000006771 Gonadotropins Human genes 0.000 claims abstract description 16
- 108010086677 Gonadotropins Proteins 0.000 claims abstract description 16
- 239000002622 gonadotropin Substances 0.000 claims abstract description 16
- 239000005557 antagonist Substances 0.000 claims abstract description 15
- 230000016087 ovulation Effects 0.000 claims abstract description 15
- 238000011161 development Methods 0.000 claims abstract description 12
- 230000000638 stimulation Effects 0.000 claims abstract description 9
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 8
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 229940011871 estrogen Drugs 0.000 claims abstract description 5
- 239000000262 estrogen Substances 0.000 claims abstract description 5
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims abstract 8
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims abstract 8
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims abstract 8
- 238000007920 subcutaneous administration Methods 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 21
- 239000000556 agonist Substances 0.000 claims description 8
- 230000002611 ovarian Effects 0.000 claims description 8
- 229940094892 gonadotropins Drugs 0.000 claims description 6
- 230000027758 ovulation cycle Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 230000029849 luteinization Effects 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000008217 follicular development Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 108700012941 GNRH1 Proteins 0.000 abstract description 12
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract description 5
- 108700008462 cetrorelix Proteins 0.000 abstract description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract description 2
- 229960003230 cetrorelix Drugs 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 15
- 108010073521 Luteinizing Hormone Proteins 0.000 description 15
- 229940040129 luteinizing hormone Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000002028 premature Effects 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100257817 Caenorhabditis elegans hmg-3 gene Proteins 0.000 description 1
- 101100395331 Caenorhabditis elegans hmg-5 gene Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/06—Bioreactors or fermenters specially adapted for specific uses for in vitro fertilization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1128296P | 1996-02-07 | 1996-02-07 | |
| US60/011282 | 1996-02-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009096656A Division JP2009155345A (ja) | 1996-02-07 | 2009-04-13 | 不妊症を治療するための製薬学的製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09227404A true JPH09227404A (ja) | 1997-09-02 |
Family
ID=21749681
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9022359A Pending JPH09227404A (ja) | 1996-02-07 | 1997-02-05 | 不妊症を治療するための製薬学的製剤 |
| JP2009096656A Pending JP2009155345A (ja) | 1996-02-07 | 2009-04-13 | 不妊症を治療するための製薬学的製剤 |
| JP2012288298A Pending JP2013056949A (ja) | 1996-02-07 | 2012-12-28 | 不妊症を治療するための製薬学的製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009096656A Pending JP2009155345A (ja) | 1996-02-07 | 2009-04-13 | 不妊症を治療するための製薬学的製剤 |
| JP2012288298A Pending JP2013056949A (ja) | 1996-02-07 | 2012-12-28 | 不妊症を治療するための製薬学的製剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7393834B2 (enExample) |
| EP (1) | EP0788799A3 (enExample) |
| JP (3) | JPH09227404A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541122A (ja) * | 1999-03-31 | 2002-12-03 | ツェンタリス アクチエンゲゼルシャフト | プログラム管理された卵巣刺激プロトコルのための方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| EP0788799A3 (en) | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| EP1082129B1 (en) | 1998-04-23 | 2003-10-29 | Zentaris AG | Method for the treatment of fertility disorders |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| US20030186892A1 (en) * | 2002-03-28 | 2003-10-02 | Rajneesh Taneja | Enhancement of endogenous gonadotropin production |
| PL373991A1 (en) * | 2002-06-07 | 2005-09-19 | Ares Trading S.A. | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| PT2621517E (pt) | 2010-09-29 | 2015-10-16 | Ferring Bv | Composição para uso no tratamento da infertilidade |
| US20240123021A1 (en) | 2021-06-25 | 2024-04-18 | Extrovis Ag | Pharmaceutical compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4342091A1 (de) | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
| EP0788799A3 (en) | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| US5945128A (en) | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| DE19712718C2 (de) | 1997-03-26 | 1999-09-23 | Asta Medica Ag | Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung |
| EP1082129B1 (en) * | 1998-04-23 | 2003-10-29 | Zentaris AG | Method for the treatment of fertility disorders |
| US8173592B1 (en) * | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
-
1997
- 1997-01-21 EP EP97100852A patent/EP0788799A3/en not_active Withdrawn
- 1997-02-05 JP JP9022359A patent/JPH09227404A/ja active Pending
-
2003
- 2003-09-15 US US10/661,780 patent/US7393834B2/en not_active Expired - Fee Related
-
2009
- 2009-04-13 JP JP2009096656A patent/JP2009155345A/ja active Pending
-
2010
- 2010-11-08 US US12/941,629 patent/US9107871B2/en not_active Expired - Fee Related
-
2012
- 2012-12-28 JP JP2012288298A patent/JP2013056949A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541122A (ja) * | 1999-03-31 | 2002-12-03 | ツェンタリス アクチエンゲゼルシャフト | プログラム管理された卵巣刺激プロトコルのための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9107871B2 (en) | 2015-08-18 |
| JP2009155345A (ja) | 2009-07-16 |
| US20050049200A1 (en) | 2005-03-03 |
| JP2013056949A (ja) | 2013-03-28 |
| EP0788799A2 (en) | 1997-08-13 |
| US7393834B2 (en) | 2008-07-01 |
| US20110306547A1 (en) | 2011-12-15 |
| EP0788799A3 (en) | 1998-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shoham et al. | Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone | |
| Diedrich et al. | Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation | |
| Shoham et al. | Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients | |
| JP2013056949A (ja) | 不妊症を治療するための製薬学的製剤 | |
| Hubayter et al. | Luteal supplementation in in vitro fertilization: more questions than answers | |
| de Ziegler et al. | Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval | |
| Charbonnel et al. | Induction of ovulation in polycystic ovary syndrome with a combination of a luteinizing hormone-releasing hormone analog and exogenous gonadotropins | |
| JPS6141451A (ja) | インビトロ受精方法 | |
| JP2005501918A (ja) | 制御下の過排卵刺激におけるｈＣＧの使用 | |
| US6653286B1 (en) | Gonadotropin releasing hormone antagonist | |
| RU2221588C2 (ru) | Способ терапевтического лечения бесплодия | |
| TWI241194B (en) | Pharmaceutical kit for treating infertility by programming of controlled ovarian stimulation and assisted reproductive procedures | |
| JPH0557864B2 (enExample) | ||
| Chang et al. | No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist | |
| Herman et al. | Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization | |
| KR20040032952A (ko) | 과배란 유도에서 ｈｃｇ와 ｌｈ의 용도 | |
| Liu et al. | Neuroendocrine control of the postpartum period | |
| Patton et al. | The use of gonadotropin-releasing hormone agonist to regulate oocyte retrieval time | |
| EA009371B1 (ru) | Способ управляемой гиперстимуляции яичников и фармацевтический набор для использования в таком способе | |
| EP0474787B1 (en) | A process for treating infertility and an agent for use in the process | |
| PL211113B1 (pl) | Zastosowanie FSH do leczenia bezpłodności | |
| Cassidenti et al. | Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report | |
| US5538948A (en) | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone | |
| CA2200541C (en) | Lhrh-antagonists in the treatment of fertility disorders | |
| Sauer et al. | Comparing the clinical utility of GnRH antagonist to GnRH agonist in an oocyte donation program |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061215 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070315 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070615 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081212 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090413 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090513 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090918 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |